Apta

In August 2015, Apta Biosciences completed its second round of funding, raising £964,550 to support product development for its new generation of special molecules.

The Story

Medical research, diagnostics and therapeutics are multi-billion dollar markets, into which Apta Biosciences is bringing breakthrough, disruptive technology that has the potential to transform the life sciences and healthcare industries.

Since its last raise, Apta has created a new generation of synthetic molecules called Seligos. Seligos are a kind of affinity reagent, which bind to specifically targeted cells in order to identify, track, capture and influence their activity to identify and treat diseases. The company is harnessing the advantages of Seligos to create new products.

The team was recently joined by Harvard academic and investor Professor Teo Forcht-Dagi, now Executive Director, whose fund has returned a staggering $6bn from $17m invested in 11 early stage companies.

This round was led by The Danish Business Angel Fund – a consortium of business angels comprising members of Business Angels Copenhagen, as well as senior executives from the life science industry (including biotech), successful entrepreneurs and company builders.

To read more about Apta Biosciences and the company’s previous funding round, click here.

D

Where are they now?

Apta is on track with its business plan, and experienced an increase in its valuation for its second round of investment. The company has obtained partnerships across the globe, including Karolinska, A-STAR, VIB, ETC, Sysmex, Perkin Elmer, Biotechne, Arkray and others. Furthermore, Apta is in the process of collaborating with hospitals, corporate partners and local institutions at proof of concept stage.

See current opportunities

UK Settled Limited

EIS
Property
Game-changing online platform reinventing the estate agency model, UK Settled Limited is backed by Facebook and Google execs.

Active

Trading status

£10,006

Average investment

£260,150

Total raised

Electrospinning

EIS
Medtech
Electrospinning makes technology that can be used in 3D printing human tissue, such as an eye or joint. Find out about there funding round here.

Active

Trading status

£10,319

Average investment

£381,790

Total raised

SeeQuestor

EIS
Transport & Logistics
Improving CCTV analysis to help solve crimes more efficiently and effectively, SeeQuestor raised funding on SyndicateRoom.

Active

Trading status

£14,065

Average investment

£872,034

Total raised

Weedingtech

EIS
Technology, Hardware & Equipment
Manufacturers of Europe’s leading herbicide-free weed control systems, Weedingtech raised funds on SyndicateRoom. Read about the raise here.

Active

Trading status

£19,543

Average investment

£801,257

Total raised

The Diabetic Boot Company

EIS
Medtech
Developing a unique wound healing device, focussed on saving diabetics from lower limb amputations. The global market for this product exceeds $1 billion.

Active

Trading status

£21,784

Average investment

£1,764,494

Total raised

Fertility Focus - Round 2

EIS
Medtech
The only product on the market that detects ovulation with 99% accuracy, Fertility Focus raised funds on SyndicateRoom. Read about the raise here.

Active

Trading status

£10,917

Average investment

£360,250

Total raised